In summary, our study highlights DCIR as an essential player in CRC immunity, paving the way for further studies to better understand the role of DCIR in tumor development and, in the longer term, for the development of pharmacological agents targeting DCIR to fight certain cancers and beyond. This evidence concerns the gene CLEC4A and cancer.